MGMT and glioblastoma: Since GBM sensitivity to standard-of-care TMZ is greatly dependent on MGMT promoter methylation status [11–13], and may also be hindered by other mechanisms [9], we first examined whether sensitivity to TTFields may also depend on MGMT expression level or on MGMT-independent cellular TMZ-resistance.